Whitepaper
Investment Insights
The success of the mRNA-based vaccine for the COVID-19 virus established that mRNA technology is highly effective in improving the body’s immune response. Messenger ribonucleic acid (mRNA) vaccines are faster and easier to mass-produce than traditional vaccines. This feature enabled biopharma companies to invest in and produce mRNA-based COVID-19 vaccines on a large scale, which was necessary to combat the pandemic. But how does one keep fundamentals over frenzy and identify the best-placed beneficiaries? And will the capital raising activity continue to remain that strong?
Key Takeaways:
To know more...
Authors
Whitepapers
China Real Estate : Possible Light at The End of The Tunnel
Since the inception of the three red lines policy, China's real estate sector has been heavily impacted by it, which is leading to a liquidity crunch in...
